Influence of aggregation on immunogenicity of recombinant human factor VIII in hemophilia A mice

Journal of Pharmaceutical Sciences

Volumn 95, Issue 2, 2006, Pages 358-371

  Purohit, Vivek S ^a   Middaugh, C Russell ^b   Balasubramanian, Sathyamangalam V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Circular dichroism; Fluorescence spectroscopy; Hemophilia A; Immunogenicity; Immunology; Inhibitor development; Protein aggregation; Protein structure; Recombinant human Factor VIII

Indexed keywords

ANTIBODY; ANTIGEN; CATHEPSIN B; CYTOKINE; EPITOPE; MONOMER; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIGEN PRESENTATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOPHILIA A; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; SPLEEN CELL; STRESS;

EID: 32644434554     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20529     Document Type: Article

References (50)

1. Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster BW, Coe ML, Knutson GJ, Fass DN, Hewick RN. 1984. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312:342-347.
2. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RD, Capon DJ. 1984. Structure of human factor VIII. Nature 312:337-342.
3. Kaufman RJ, Wasley LC, Dorner AJ. 1988. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 263:6352-6362.
4. Foster PA, Zimmerman TS. 1989. Factor VIII structure and function. Blood Reviews 3:180-191.
5. Fay PJ. 1988. Reconstitution of human factor VIII from isolated subunits. Arch Biochem Biophys 262: 525-531.
6. VanAken WG. 1997. The potential impact of recombinant factor VIII on hemophilia care and the demand for blood and blood products. Transfus Med Rev 11:6-14.
7. Jacquemin MG, Saint-Remy JM. 1998. Factor VIII immunogenicity. Haemophilia 4:552-557.
8. Lollar P, Healey JF, Barrow RT, Parker ET. 2001. Factor VIII inhibitors. Adv Exp Med Biol 489:65-73.
9. Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J. 2004. Inhibitors in haemophilia: pathophysiology. Haemophilia 10:146-151.
10. Oldenburg J, Schroder J, Hermann Brackmann H, Muller-Reible C, Schwaab R, Tuddenham E. 2004. Environmental and genetic factors influencing inhibitor development. Semin Hematol 41: 82-88.
11. Wills RJ, Ferraiolo BL. 1992. The role of pharmacokinetics in the development of biotechnologically derived agents. Clin Pharmacokinet 23:406-414.
12. Schellekens H. 2002. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720-1740; discussion 1719.
13. Schellekens H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457-462.
14. Ryff JC, Schellekens H. 2002. Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol Sci 23:254-256.
15. Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14:1472-1478.
16. Wang W, Kelner DN. 2003. Correlation of rFVIII inactivation with aggregation in solution. Pharm Res 20:693-700.
17. Patten PA, Schellekens H. 2003. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev Biol (Basel) 112:81-97.
18. Moore WV, Leppert P. 1980. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51: 691-697.
19. Ramani K, Purohit VS, Miclea RD, Middaugh CR, Balasubramanian SV. 2005. Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII). J Pharm Sci 94:1288-1299.
20. Grillo AO, Edwards KL, Kashi RS, Shipley KM, Hu L, Besman MJ, Middaugh CR. 2001. Conformational origin of the aggregation of recombinant human factor VIII. Biochemistry 40:586-595.
21. Cho Y, Garanchon C, Kashi R, Wong C, Besman MJ. 1996. Characterization of aggregates of recombinant human factor VIII by size-exclusion chromatography and immunoassay. Biotechnol Appl Biochem 24:55-59.
22. Lakowicz JR. 1999. Principles of fluorescence spectroscopy, 2nd ed. New York: Kluwer Academic/Plenum Publishers.
23. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH, Jr. 1995. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 10: 119-121.
24. Qian J, Borovok M, Bi L, Kazazian HH, Jr., Hoyer LW. 1999. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 81:240-244.
25. Reipert BM, Ahmad RU, Turecek PL, Schwarz HP. 2000. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 84:826-832.
26. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. 2002. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 88:221-229.
27. Pratt KP, Qian J, Ellaban E, Okita DK, Diethelm-Okita BM, Conti-Fine B, Scott DW. 2004. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost 92:522-528.
28. http://www.baxter.com/products/biopharmaceuticals/downloads/Advate_PI. pdf.
29. Remmele RL, Jr., Gombotz WR. 2000. Differential scanning calorimetry: a practical tool for elucidating stability of liquid pharmaceuticals. BioPharm 13:36-46.
30. Tsai PK, Volkin DB, Dabora JM, Thompson KC, Bruner MW, Gress JO, Matuszewska B, Keogan M, Bondi JV, Middaugh CR. 1993. Formulation design of acidic fibroblast growth factor. Pharm Res 10: 649-659.
31. Purohit VS, Ramani K, Sarkar R, Kazazian HH, Jr., Balasubramanian SV. 2005. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem 280:17593-17600.
32. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. 1995. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 73:247-251.
33. Ramani K, Purohit V, Middaugh CR, Balasubramanian SV. 2005. Aggregation kinetics of recombinant human FVIII (rFVIII). J Pharm Sci 94:2023-2029.
34. Reipert BM, Schoppmann A, Schwarz HP. 2003. A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions. Thromb Haemost 89:1110-1112; author reply 1113.
35. Hunt JD, Jackson DC, Wood PR, Stewart DJ, Brown LE. 1995. Immunological parameters associated with antigenic competition in a multivalent footrot vaccine. Vaccine 13:1649-1657.
36. Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW, Conti-Fine BM. 2001. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 85:125-133.
37. Thai R, Moine G, Desmadril M, Servent D, Tarride JL, Menez A, Leonetti M. 2004. Antigen stability controls antigen presentation. J Biol Chem 279: 50257-50266.
38. Khalili-Shirazi A, Quaratino S, Londei M, Summers L, Tayebi M, Clarke AR, Hawke SH, Jackson GS, Collinge J. 2005. Protein conformation significantly influences immune responses to prion protein. J Immunol 174:3256-3263.
39. Grundner C, Pancera M, Kang JM, Koch M, Sodroski J, Wyatt R. 2004. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology 330:233-248.
40. Sasgary M, Ahmad RU, Schwarz HP, Turecek PL, Reipert BM. 2002. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 87:266-272.
41. Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. 2002. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 88:568-575.
42. Charles JA, Travers P, Walport M, Capra JD. 1999. The induction and detection of immune responses. Immunobiology: the immune system in health and disease, 4th ed. New York: Elsevier Science Ltd/Garland Publishing, pp 36-37.
43. Katunuma N, Matsunaga Y, Himeno K, Hayashi Y. 2003. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. Biol Chem 384:883-890.
44. Watts C. 1997. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15:821-850.
45. Parker DC. 1993. T cell-dependent B cell activation. Annu Rev Immunol 11:331-360.
46. Constant SL, Bottomly K. 1997. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 15:297-322.
47. Speidel K, Osen W, Faath S, Hilgert I, Obst R, Braspenning J, Momburg F, Hammerling GJ, Rammensee HG. 1997. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol 27:2391-2399.
48. Koch C, Jensen SS, Oster A, Houen G. 1996. A comparison of the immunogenicity of the native and denatured forms of a protein. APMIS 104:115-125.
49. Magi M, Garcia L, Vandenbranden M, Palmantier R, Jacquet A. 2004. Heat denaturation affects the ProDer p 1 IgE reactivity and downregulates the development of the specific allergic response. J Allergy Clin Immunol 114:545-552.
50. Babiuk S, Skowronski DM, De Serres G, HayGlass K, Brunham RC, Babiuk L. 2004. Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model. J Med Virol 72:138-142.